ClinicalTrials.gg
CompletedNCT02762799Updated Dec 19, 2018Results posted

Clinical Trial to Evaluate Pharmacokinetics, Pharmacodynamics and Safety of Leucostim® Compared to Neupogen®

A Phase 1 interventional study of Leucostim® and Neupogen® in Leucocytosis, sponsored by Biocad. Completed. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-12-19.

Sponsored by Biocad · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Male
01

Study summary

BCD-002-1 is 1 phase clinical trial to evaluate pharmacokinetics, pharmacodynamics and safety of single-injection of Leucostim® to healthy volunteers compared to Neupogen®

02

Conditions studied

  • Leucocytosis

Keywords

  • neutrophil count
  • filgrastim
  • granulocyte colony-stimulating factor
03

In context

Lead sponsor

Biocad is the lead sponsor of 94 studies on the registry; 12 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written .
  • Male gender.
  • Age between 18 and 45 years.
  • Normal .
  • Verified diagnosis "healthy", established according to the anamnesis, physical examination and laboratory findings.
  • Absence of alcohol or drug abuse.

Exclusion criteria

Exclusion Criteria:

  • History of use of filgrastim.
  • Allergy to any components of study drugs.
  • Acute hemorrhage, donation of blood / plasma or blood transfusions during last 2 months prior to enrollment in the study, history of chronic bleeding.
  • Surgical interventions during last 30 days prior to screening or planed surgical intervention during the study.
  • Any diseases that could interfere with pharmacokinetics of filgrastim, including chronic liver, liver or blood diseases, diseases of cardiovascular, lung and neuroendocrine systems.
  • Fever with body temperature higher than 40°С.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    Leucostim® --> Neupogen®, subcutaneous injections

    Healthy volunteers in this group will receive single subcutaneous injection Leucostim® on Day 1 followed by single subcutaneous injection Leucostim® on Day 29.

    Biological: Leucostim® · Biological: Neupogen®

  • Experimental
    Neupogen® --> Leucostim®, subcutaneous injections

    Healthy volunteers in this group will receive single subcutaneous injection Neupogen®, on Day 1 followed by single subcutaneous injection Leucostim® on Day 29.

    Biological: Leucostim® · Biological: Neupogen®

  • Experimental
    Leucostim® --> Neupogen®, intravenous injections

    Healthy volunteers in this group will receive single intravenous injection Leucostim® on Day 1 followed by single intravenous injection Leucostim® on Day 29.

    Biological: Leucostim® · Biological: Neupogen®

  • Experimental
    Neupogen® --> Leucostim®, intravenous injections

    Healthy volunteers in this group will receive single intravenous injection Neupogen® on Day 1 followed by single subcutaneous intravenous Leucostim® on Day 29.

    Biological: Leucostim® · Biological: Neupogen®

Interventions

  • BiologicalLeucostim®

    Leucostim® is filgrastim biosimilar.

    Also known as: filgrastim

  • BiologicalNeupogen®

    Also known as: filgrastim

06

What researchers measure

Primary outcomes

  1. AUC (0-48 Hours)

    Area Under Curve (AUC) "concentration - time" from the moment of filgrastim injection to 48 hours

    Time frame: 0 to 48 hours post-dose

  2. Cmax After Subcutaneous Injection

    Maximal concentration of filgrastim after subcutaneous injection of filgrastim

    Time frame: 0 to 48 hours post-dose

Secondary outcomes

  1. Cmax After Intravenous Injection

    Maximal concentration of filgrastim after intravenous injection of filgrastim

    Time frame: 0 to 48 hours post-dose

  2. Tmax After Injection

    Time after single injection to reach maximal concentration of filgrastim

    Time frame: 0 to 48 hours post-dose

  3. Т½

    Half-life of filgrastim after single injection of filgrastim

    Time frame: 0 to 48 hours post-dose

  4. Kel

    The elimination rate constant after single injection of filgrastim

    Time frame: 0 to 48 hours post-dose

  5. Clearance

    Clearance of filgrastim after single injection

    Time frame: 0 to 48 hours post-dose

  6. ANC-AUEC (0-336 Hours)

    Area Under Effect Curve (AUEC) "effect - time" from the moment of filgrastim injection to 336 hours based on absolute neutrophil count (ANC)

    Time frame: 0 to 336 hours post-dose

  7. ANC-Emax

    Maximal absolute neutrophil count after single filgrastim injection

    Time frame: 0 to 336 hours post-dose

  8. CD34-AUEC (0-336 Hours)

    Area Under Effect Curve (AUEC) "effect - time" from the moment of filgrastim injection to 336 hours based on CD-34 cells count (CD34)

    Time frame: 0 to 336 hours post-dose

  9. CD34-Emax

    Maximal absolute count of CD34-cells after single filgrastim injection

    Time frame: 0 to 336 hours post-dose

  10. Overall Frequency of Serious Adverse Events (SAE)

    Time frame: 0 to 336 hours post-dose

  11. Overall Frequency of Adverse Events (AE)

    Time frame: 0 to 336 hours post-dose

  12. Frequency of Local Reactions

    Time frame: 0 to 336 hours post-dose

  13. Frequency of AE/SAE 3-4 Grade CTCAE 4.03

    Grading scale of CTCAE 4.03 Grade refers to the severity of the AE. The CTCAE displays Grades 1 through 5 with unique clinical descriptions of severity for each AE: Grade 1 Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. Grade 2 Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental ADL (activities of daily living). Grade 3 Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care ADL. Grade 4 Life-threatening consequences; urgent intervention indicated. Grade 5 Death related to AE.

    Time frame: 0 to 336 hours post-dose

  14. Frequency of Preliminary Withdrawal Due to AE/SAE

    Time frame: 0 to 336 hours post-dose

  15. Proportion of Patients With Binding or Neutralizing Antibodies to Filgrastim

    Proportion of patients who had developed binding or neutralizing antibodies to filgrastim after single injection.

    Time frame: 0 to 336 hours post-dose

07

Results

Posted Dec 19, 2018

Participant flow

Participant flow — Overall Study
MilestoneLeucostim® --> Neupogen®, Subcutaneous InjectionsNeupogen® --> Leucostim®, Subcutaneous InjectionsLeucostim® --> Neupogen®, Intravenous InjectionsNeupogen® --> Leucostim®, Intravenous Injections
Started18181212
Completed18181112
Not completed0010

Outcome measures

PrimaryAUC (0-48 Hours)

Area Under Curve (AUC) "concentration - time" from the moment of filgrastim injection to 48 hours

Time frame:
0 to 48 hours post-dose
Reported as:
Geometric mean · picogram per ml / hour
AUC (0-48 Hours)
picogram per ml / hourLeucostim® Subcutaneous InjectionsNeupogen® Subcutaneous InjectionsLeucostim® Intravenous InjectionsNeupogen® Intravenous Injections
AUC (0-48 Hours)168603.588 ± 47721.48181152 ± 54706.439411826.811 ± 204285.095427355.99 ± 170878.6
PrimaryCmax After Subcutaneous Injection

Maximal concentration of filgrastim after subcutaneous injection of filgrastim

Time frame:
0 to 48 hours post-dose
Reported as:
Geometric mean · picogram per ml
Cmax After Subcutaneous Injection
picogram per mlLeucostim® Subcutaneous InjectionsNeupogen® Subcutaneous Injections
Cmax After Subcutaneous Injection21605.163 ± 5247.46723389.559 ± 7549.536
SecondaryCmax After Intravenous Injection

Maximal concentration of filgrastim after intravenous injection of filgrastim

Time frame:
0 to 48 hours post-dose
Reported as:
Geometric mean · picogram per ml
Cmax After Intravenous Injection
picogram per mlLeucostim® Intravenous InjectionsNeupogen® Intravenous Injections
Cmax After Intravenous Injection79751.577 ± 24810.90790796.227 ± 25925.283
SecondaryTmax After Injection

Time after single injection to reach maximal concentration of filgrastim

Time frame:
0 to 48 hours post-dose
Reported as:
Median · hours
Tmax After Injection
hoursLeucostim® Subcutaneous InjectionsNeupogen® Subcutaneous InjectionsLeucostim® Intravenous InjectionsNeupogen® Intravenous Injections
Tmax After Injection4 (4 to 4)4 (4 to 6)0.5 (0.5 to 2)0.5 (0.5 to 0.5)
SecondaryТ½

Half-life of filgrastim after single injection of filgrastim

Time frame:
0 to 48 hours post-dose
Reported as:
Median · hours
Т½
hoursLeucostim® Subcutaneous InjectionsNeupogen® Subcutaneous InjectionsLeucostim® Intravenous InjectionsNeupogen® Intravenous Injections
Т½4,386 (3,889 to 4,914)4,307 (4,025 to 4,757)2,746 (2,178 to 2,951)2,549 (2,079 to 3,136)
SecondaryKel

The elimination rate constant after single injection of filgrastim

Time frame:
0 to 48 hours post-dose
Reported as:
Mean · hour-1
Kel
hour-1Leucostim® Subcutaneous InjectionsNeupogen® Subcutaneous InjectionsLeucostim® Intravenous InjectionsNeupogen® Intravenous Injections
Kel0.158 (0.141 to 0.173)0.161 (0.145 to 0.17)0.252 (0.173 to 0.318)0.272 (0.219 to 0.316)
SecondaryClearance

Clearance of filgrastim after single injection

Time frame:
0 to 48 hours post-dose
Reported as:
Median · ml per hour
Clearance
ml per hourLeucostim® Subcutaneous InjectionsNeupogen® Subcutaneous InjectionsLeucostim® Intravenous InjectionsNeupogen® Intravenous Injections
Clearance2048.087 (1893.882 to 2518.863)1981.707 (1581.655 to 2439.947)965.938 (595.547 to 1055.471)830.442 (724.578 to 941.928)
SecondaryANC-AUEC (0-336 Hours)

Area Under Effect Curve (AUEC) "effect - time" from the moment of filgrastim injection to 336 hours based on absolute neutrophil count (ANC)

Time frame:
0 to 336 hours post-dose
Reported as:
Geometric mean · cells х10^9 per liter/hour
ANC-AUEC (0-336 Hours)
cells х10^9 per liter/hourLeucostim® Subcutaneous InjectionsNeupogen® Subcutaneous InjectionsLeucostim® Intravenous InjectionsNeupogen® Intravenous Injections
ANC-AUEC (0-336 Hours)1924.284 ± 326.4551933.358 ± 309.5331860.922 ± 372.8611895.82 ± 426.826
SecondaryANC-Emax

Maximal absolute neutrophil count after single filgrastim injection

Time frame:
0 to 336 hours post-dose
Reported as:
Geometric mean · cells х10^9 per liter
ANC-Emax
cells х10^9 per literLeucostim® Subcutaneous InjectionsNeupogen® Subcutaneous InjectionsLeucostim® Intravenous InjectionsNeupogen® Intravenous Injections
ANC-Emax21.285 ± 4.59320.803 ± 4.09720.726 ± 6.39321.602 ± 5.93
SecondaryCD34-AUEC (0-336 Hours)

Area Under Effect Curve (AUEC) "effect - time" from the moment of filgrastim injection to 336 hours based on CD-34 cells count (CD34)

Time frame:
0 to 336 hours post-dose
Reported as:
Mean · cell per microliter / hour
CD34-AUEC (0-336 Hours)
cell per microliter / hourLeucostim® Subcutaneous InjectionsNeupogen® Subcutaneous InjectionsLeucostim® Intravenous InjectionsNeupogen® Intravenous Injections
CD34-AUEC (0-336 Hours)1289 ± 762.2921200.667 ± 761.291350.783 ± 716.6451251.652 ± 562.087
SecondaryCD34-Emax

Maximal absolute count of CD34-cells after single filgrastim injection

Time frame:
0 to 336 hours post-dose
Reported as:
Mean · cell per microliter
CD34-Emax
cell per microliterLeucostim® Subcutaneous InjectionsNeupogen® Subcutaneous InjectionsLeucostim® Intravenous InjectionsNeupogen® Intravenous Injections
CD34-Emax7.694 ± 4.8397.056 ± 5.2489 ± 6.2677.522 ± 4.22
SecondaryOverall Frequency of Serious Adverse Events (SAE)
Time frame:
0 to 336 hours post-dose
Reported as:
Count of participants · Participants
Overall Frequency of Serious Adverse Events (SAE)
ParticipantsLeucostim® Subcutaneous InjectionsNeupogen® Subcutaneous InjectionsLeucostim® Intravenous InjectionsNeupogen® Intravenous Injections
Overall Frequency of Serious Adverse Events (SAE)0000
SecondaryOverall Frequency of Adverse Events (AE)
Time frame:
0 to 336 hours post-dose
Reported as:
Count of participants · Participants
Overall Frequency of Adverse Events (AE)
ParticipantsLeucostim® Subcutaneous InjectionsNeupogen® Subcutaneous InjectionsLeucostim® Intravenous InjectionsNeupogen® Intravenous Injections
Overall Frequency of Adverse Events (AE)36352222
SecondaryFrequency of Local Reactions
Time frame:
0 to 336 hours post-dose
Reported as:
Count of participants · Participants
Frequency of Local Reactions
ParticipantsLeucostim® Subcutaneous InjectionsNeupogen® Subcutaneous InjectionsLeucostim® Intravenous InjectionsNeupogen® Intravenous Injections
Frequency of Local Reactions0000
SecondaryFrequency of AE/SAE 3-4 Grade CTCAE 4.03

Grading scale of CTCAE 4.03 Grade refers to the severity of the AE. The CTCAE displays Grades 1 through 5 with unique clinical descriptions of severity for each AE: Grade 1 Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. Grade 2 Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental ADL (activities of daily living). Grade 3 Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care ADL. Grade 4 Life-threatening consequences; urgent intervention indicated. Grade 5 Death related to AE.

Time frame:
0 to 336 hours post-dose
Reported as:
Count of participants · Participants
Frequency of AE/SAE 3-4 Grade CTCAE 4.03
ParticipantsLeucostim® Subcutaneous InjectionsNeupogen® Subcutaneous InjectionsLeucostim® Intravenous InjectionsNeupogen® Intravenous Injections
Frequency of AE/SAE 3-4 Grade CTCAE 4.030100
SecondaryFrequency of Preliminary Withdrawal Due to AE/SAE
Time frame:
0 to 336 hours post-dose
Reported as:
Count of participants · Participants
Frequency of Preliminary Withdrawal Due to AE/SAE
ParticipantsLeucostim® Subcutaneous InjectionsNeupogen® Subcutaneous InjectionsLeucostim® Intravenous InjectionsNeupogen® Intravenous Injections
Frequency of Preliminary Withdrawal Due to AE/SAE0000
SecondaryProportion of Patients With Binding or Neutralizing Antibodies to Filgrastim

Proportion of patients who had developed binding or neutralizing antibodies to filgrastim after single injection.

Time frame:
0 to 336 hours post-dose
Reported as:
Count of participants · Participants
Proportion of Patients With Binding or Neutralizing Antibodies to Filgrastim
ParticipantsLeucostim® Subcutaneous InjectionsNeupogen® Subcutaneous InjectionsLeucostim® Intravenous InjectionsNeupogen® Intravenous Injections
Proportion of Patients With Binding or Neutralizing Antibodies to Filgrastim0000

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Leucostim®, Subcutaneous Injections0/36 (0%)0/36 (0%)36/36 (100%)
Neupogen® Subcutaneous Injections0/36 (0%)0/36 (0%)35/36 (97.2%)
Leucostim®, Intravenous Injections0/24 (0%)0/24 (0%)22/24 (91.7%)
Neupogen®, Intravenous Injections0/23 (0%)0/23 (0%)22/23 (95.7%)
Most frequent other events
Most frequent other events
EventLeucostim®, Subcutaneous InjectionsNeupogen® Subcutaneous InjectionsLeucostim®, Intravenous InjectionsNeupogen®, Intravenous Injections
MonocytosisBlood and lymphatic system disorders32/3632/3620/2421/23
eosinophiliaBlood and lymphatic system disorders10/3615/369/247/23
LymphocytosisBlood and lymphatic system disorders11/3610/365/242/23
head painNervous system disorders9/3610/360/240/23

Baseline characteristics

Age, Continuous
Age, Continuous(years)Leucostim® --> Neupogen®, Subcutaneous InjectionsNeupogen® --> Leucostim®, Subcutaneous InjectionsLeucostim® --> Neupogen®, Intravenous InjectionsNeupogen® --> Leucostim®, Intravenous InjectionsTotal
Median22.94 (21.79 to 26.49)25.41 (22.45 to 29.58)23.48 (21.81 to 26.97)27.30 (24.61 to 27.78)24.63 (22.35 to 27.41)
Sex: Female, Male
Sex: Female, Male(Participants)Leucostim® --> Neupogen®, Subcutaneous InjectionsNeupogen® --> Leucostim®, Subcutaneous InjectionsLeucostim® --> Neupogen®, Intravenous InjectionsNeupogen® --> Leucostim®, Intravenous InjectionsTotal
Female00000
Male1818121260
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)Leucostim® --> Neupogen®, Subcutaneous InjectionsNeupogen® --> Leucostim®, Subcutaneous InjectionsLeucostim® --> Neupogen®, Intravenous InjectionsNeupogen® --> Leucostim®, Intravenous InjectionsTotal
Count of participants————0
08

Study locations

No study locations are listed for this record.

09

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2016 to primary completion in Nov 2016, 3 months.

Results were first posted in Dec 2018, 2 years 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 1, 2016
First posted
May 5, 2016
StartActual
Jul 18, 2016
Primary completionActual
Nov 11, 2016
CompletionActual
Nov 11, 2016
Results first posted
Dec 19, 2018
Last update
Dec 19, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 19, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02762799
Lead sponsor
Biocad
Responsible party
Sponsor
First posted
May 5, 2016
Start date
Jul 18, 2016
Primary completion
Nov 11, 2016
Completion
Nov 11, 2016
Results posted
Dec 19, 2018
Last update
Dec 19, 2018

Study contacts

Roman Ivanov, PhD
study chair · JCS BIOCAD

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Filgrastim

Start the discussion